Turning Microbial AhR Agonists into Therapeutic Agents via Drug Delivery Systems
Pharmaceutics · 03.02.2023 · 15 (2) · 506
DOI: 10.3390/pharmaceutics15020506 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 03.02.2023. Verfasst von Matteo Puccetti und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, University of Perugia, 06123 Perugia, Italy. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondazione per la Ricerca sulla Fibrosi Cistica.
Abstract (Originalsprache)
Developing therapeutics for inflammatory diseases is challenging due to physiological mucosal barriers, systemic side effects, and the local microbiota. In the search for novel methods to overcome some of these problems, drug delivery systems that improve tissue-targeted drug delivery and modulate the microbiota are highly desirable. Microbial metabolites are known to regulate immune responses, an observation that has resulted in important conceptual advances in areas such as metabolite pharmacology and metabolite therapeutics. Indeed, the doctrine of “one molecule, one target, one disease” that has dominated the pharmaceutical industry in the 20th century is being replaced by developing therapeutics which simultaneously manipulate multiple targets through novel formulation approaches, including the multitarget-directed ligands. Thus, metabolites may not only represent biomarkers for disease development, but also, being causally linked to human diseases, an unexploited source of therapeutics. We have shown the successful exploitation of this approach: by deciphering how signaling molecules, such as the microbial metabolite, indole-3-aldehyde, and the repurposed drug anakinra, interact with the aryl hydrocarbon receptor may pave the way for novel therapeutics in inflammatory human diseases, for the realization of which drug delivery platforms are instrumental.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, University of Perugia, 06123 Perugia, Italy.
- Department of Medicine, University of Perugia, 06132 Perugia, Italy.
ORCID-Profile: Matteo Puccetti, Aurélie Schoubben, Stefano Giovagnoli, Maurizio Ricci
Förderung
- Fondazione per la Ricerca sulla Fibrosi Cistica
Zitieren
APA
Puccetti, M., Pariano, M., Wojtylo, P., Schoubben, A., Giovagnoli, S., & Ricci, M. (2023). Turning Microbial AhR Agonists into Therapeutic Agents via Drug Delivery Systems. Pharmaceutics, 15(2), 506. https://doi.org/10.3390/pharmaceutics15020506
Vancouver
Puccetti M, Pariano M, Wojtylo P, Schoubben A, Giovagnoli S, Ricci M. Turning Microbial AhR Agonists into Therapeutic Agents via Drug Delivery Systems. Pharmaceutics. 2023;15(2):506. doi:10.3390/pharmaceutics15020506
BibTeX
@article{Puccetti2023,
author = {Puccetti, Matteo and Pariano, Marilena and Wojtylo, Paulina and Schoubben, Aurélie and Giovagnoli, Stefano and Ricci, Maurizio},
title = {Turning Microbial AhR Agonists into Therapeutic Agents via Drug Delivery Systems},
journal = {Pharmaceutics},
year = {2023},
volume = {15},
number = {2},
pages = {506},
doi = {10.3390/pharmaceutics15020506}
}
EUVIMED